Which neurotransmitter has both muscarinic and nicotinic receptor subtypes?

Choice A reason: Intervening in self-harm prioritizes beneficence, ensuring safety, over autonomy. Self-mutilation, often linked to dysregulated serotonin or impulsivity, requires immediate action to prevent harm, overriding patient choice. Autonomy is secondary when safety is at risk, making this an incorrect application of the principle.

Choice B reason: Exploring medication options respects autonomy by involving patients in decisions, aligning with their values. This considers individual neurobiological responses (e.g., serotonin reuptake variations) and preferences, empowering informed choice. Autonomy emphasizes patient control over treatment, making this the correct approach for ethical psychiatric care.

Choice C reason: Restricting patients for fighting prioritizes safety and unit order, not autonomy. Conflict may stem from emotional dysregulation or neurotransmitter imbalances, but restricting movement limits patient choice. This action reflects beneficence or justice, not autonomy, making it an incorrect choice for this ethical principle.

Choice D reason: Staying with an anxious patient supports emotional regulation, possibly linked to GABA deficits, but emphasizes beneficence over autonomy. While supportive, it does not involve patient decision-making. Autonomy requires empowering patient choice, not just presence, making this an incorrect application of the ethical principle.

Choice A reason: Decreasing dopamine is used for disorders like schizophrenia, where excess mesolimbic dopamine causes hallucinations. Memory difficulties, often linked to Alzheimer’s, involve cholinergic deficits, not dopamine excess. Reducing dopamine could worsen cognition by disrupting reward and attention pathways, making this approach scientifically inappropriate for memory issues.

Choice B reason: Inhibiting GABA production is irrelevant for memory. GABA regulates neural inhibition, and its reduction could increase excitability, worsening conditions like seizures. Memory deficits, particularly in dementia, stem from reduced acetylcholine in the hippocampus, not GABA, making this option misaligned with the neurobiology of memory impairment.

Choice C reason: Preventing acetylcholine destruction, via cholinesterase inhibitors, enhances cholinergic activity in the hippocampus and cortex, critical for memory in conditions like Alzheimer’s. Low acetylcholine levels impair neural signaling, causing memory deficits. This approach directly addresses the neurochemical basis of memory difficulties, making it scientifically appropriate for treatment.

Choice D reason: Increasing dopamine sensitivity is relevant for disorders like Parkinson’s, not memory deficits. Dopamine affects motivation and movement, not memory, which relies on acetylcholine in the hippocampus. Enhancing dopamine could disrupt cognitive balance, worsening memory without addressing the cholinergic deficits central to memory impairment.